These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32040670)

  • 21. Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes.
    Nativel M; Schneider F; Saulnier PJ; Gand E; Ragot S; Meilhac O; Rondeau P; Burillo E; Cournot M; Potier L; Velho G; Marre M; Roussel R; Rigalleau V; Mohammedi K; Hadjadj S
    Diabetes Care; 2018 Oct; 41(10):2162-2169. PubMed ID: 30072406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes.
    Niersmann C; Carstensen-Kirberg M; Maalmi H; Holleczek B; Roden M; Brenner H; Herder C; Schöttker B
    Diabetologia; 2020 Feb; 63(2):410-418. PubMed ID: 31705160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up.
    Lenart-Lipińska M; Matyjaszek-Matuszek B; Gernand W; Nowakowski A; Solski J
    Diabetes Res Clin Pract; 2013 Aug; 101(2):194-200. PubMed ID: 23768789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort.
    Saulnier PJ; Gand E; Ragot S; Ducrocq G; Halimi JM; Hulin-Delmotte C; Llaty P; Montaigne D; Rigalleau V; Roussel R; Velho G; Sosner P; Zaoui P; Hadjadj S;
    Diabetes Care; 2014 May; 37(5):1425-31. PubMed ID: 24623026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy.
    Tada H; Nomura A; Yoshimura K; Itoh H; Komuro I; Yamagishi M; Takamura M; Kawashiri MA
    Circ J; 2020 Feb; 84(3):509-515. PubMed ID: 32023582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes.
    Nowak C; Carlsson AC; Östgren CJ; Nyström FH; Alam M; Feldreich T; Sundström J; Carrero JJ; Leppert J; Hedberg P; Henriksen E; Cordeiro AC; Giedraitis V; Lind L; Ingelsson E; Fall T; Ärnlöv J
    Diabetologia; 2018 Aug; 61(8):1748-1757. PubMed ID: 29796748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30).
    Landman GW; van Dijk PR; Drion I; van Hateren KJ; Struck J; Groenier KH; Gans RO; Bilo HJ; Bakker SJ; Kleefstra N
    Diabetes Care; 2014; 37(3):839-45. PubMed ID: 24170764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
    Raparelli V; Pastori D; Pignataro SF; Vestri AR; Pignatelli P; Cangemi R; Proietti M; Davì G; Hiatt WR; Lip GYH; Corazza GR; Perticone F; Violi F; Basili S;
    Intern Emerg Med; 2018 Aug; 13(5):651-660. PubMed ID: 29582316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study).
    Lindberg S; Mogelvang R; Pedersen SH; Bjerre M; Frystyk J; Flyvbjerg A; Galatius S; Jensen JS
    Am J Cardiol; 2013 Apr; 111(8):1139-45. PubMed ID: 23375598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).
    Vaduganathan M; White WB; Charytan DM; Morrow DA; Liu Y; Zannad F; Cannon CP; Bakris GL;
    Am J Cardiol; 2019 Feb; 123(3):382-391. PubMed ID: 30477800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
    Li WP; Neradilek MB; Gu FS; Isquith DA; Sun ZJ; Wu X; Li HW; Zhao XQ
    Cardiovasc Diabetol; 2017 Apr; 16(1):45. PubMed ID: 28381225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adiponectin, type 2 diabetes and cardiovascular risk.
    Lindberg S; Jensen JS; Bjerre M; Pedersen SH; Frystyk J; Flyvbjerg A; Galatius S; Jeppesen J; Mogelvang R
    Eur J Prev Cardiol; 2015 Mar; 22(3):276-83. PubMed ID: 24265290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toe brachial index predicts major acute cardiovascular events in patients with type 2 diabetes independently of arterial stiffness.
    Chisalita SI; Wijkman M; Davidson LT; Spångeus A; Nyström F; Östgren CJ
    Diabetes Res Clin Pract; 2020 Mar; 161():108040. PubMed ID: 32006647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes.
    Resl M; Clodi M; Vila G; Luger A; Neuhold S; Wurm R; Adlbrecht C; Strunk G; Fritzer-Szekeres M; Prager R; Pacher R; Hülsmann M
    Heart; 2016 Dec; 102(24):1963-1968. PubMed ID: 27456261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Proenkephalin A Levels and Mortality After Long-Term Follow-Up in Patients with Type 2 Diabetes Mellitus (ZODIAC-32).
    van Hateren KJ; Landman GW; Arnold JF; Joosten H; Groenier KH; Navis GJ; Sparwasser A; Bakker SJ; Bilo HJ; Kleefstra N
    PLoS One; 2015; 10(7):e0133065. PubMed ID: 26218633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble vascular adhesion protein-1 predicts incident major adverse cardiovascular events and improves reclassification in a finnish prospective cohort study.
    Aalto K; Havulinna AS; Jalkanen S; Salomaa V; Salmi M
    Circ Cardiovasc Genet; 2014 Aug; 7(4):529-35. PubMed ID: 24850810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum T
    van der Vaart A; Eelderink C; van Goor H; Hillebrands JL; Te Velde-Keyzer CA; Bakker SJL; Pasch A; van Dijk PR; Laverman GD; de Borst MH
    J Intern Med; 2024 Jun; 295(6):748-758. PubMed ID: 38528373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low birthweight in patients with type 2 diabetes is associated with elevated risk of cardiovascular events and mortality.
    Hansen AL; Brøns C; Engelhard LM; Andersen MK; Hansen T; Nielsen JS; Vestergaard P; Højlund K; Jessen N; Olsen MH; Sørensen HT; Thomsen RW; Vaag A
    Diabetologia; 2024 Aug; 67(8):1616-1629. PubMed ID: 38777869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary Sodium Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality in a Type 2 Diabetes Cohort Population.
    Saulnier PJ; Gand E; Ragot S; Bankir L; Piguel X; Fumeron F; Rigalleau V; Halimi JM; Marechaud R; Roussel R; Hadjadj S;
    J Diabetes Res; 2017; 2017():5327352. PubMed ID: 28255559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.